logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
J

Justin P.O. Lindemann

AstraZeneca
H指数:29
被引数:3,611

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1☆

Camizestrant联合capivasertib治疗ER阳性，HER2-negative晚期乳腺癌的女性: SERENA-1 ☆ 的结果

ESMO Open
IF8.3
2026-01-210
OAAI
C. Vaklavas; M. Oliveira; A.C. Armstrong; I. Moreno; C. Twelves; I. Victoria Ruiz; B. Bermejo de las Heras; T. Brier; C. Ciardullo; L. Gibbons; T. Jack; T. Klinowska; J.P.O. Lindemann; A.M. Mathewson; R. Maudsley; C.J. Morrow; A. Sykes; R.D. Baird
A multiomic approach for camizestrant-induced estrogen receptor (ER) degradation, antagonism and anti-proliferation: Exploratory analysis from SERENA-3

一种针对卡米泽米特诱导的雌激素受体（ER）降解、拮抗和抗增殖的多组学方法：SERENA-3研究的探索性分析

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Dzagnidze, G.; Morrow, C.; Gogitidze, T.; Katashvili, Z. S.; Rocha, J. E. Bargallo; Arkania, E.; Moppett, I.; Cheung, K-L.; Nemsadze, G.; Ajimi, M.; Andreou, K.; Chambers, A.; Chain, D.; Kim, R.; Lindemann, J.; Mcewen, R.; Nikolaou, M.; Robertson, J.; Whitston, D.; Robertson, J. F.
A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results

在ER阳性，HER2-negative晚期乳腺癌女性中，下一代口服SERD camizestrant的I期剂量递增和扩展试验: SERENA-1单药治疗结果

ANNALS OF ONCOLOGY
IF65.4
2024-08-016
OAAI
Hamilton, E.; Oliveira, M.; Turner, N.; Garcia-Corbacho, J.; Hernando, C.; Ciruelos, E. M.; Kabos, P.; Ruiz-Borrego, M.; Armstrong, A.; Patel, M. R.; Vaklavas, C.; Twelves, C.; Boni, V.; Incorvati, J.; Brier, T.; Gibbons, L.; Klinowska, T.; Lindemann, J. P. O.; Morrow, C. J.; Sykes, A.; Baird, R. D.
SERENA-3: A randomized pre-surgical window of opportunity study assessing dose and duration of camizestrant treatment in post-menopausal women with ER-positive, HER2-negative primary breast cancer
CANCER RESEARCH
IF16.6
2024-05-022
PRE
Robertson, John; Gogitidze, Teimuraz; Katashvili, Zaza; Rocha, Juan Enrique Bargallo; Arkania, Ekaterine; Moppett, Iain; Cheung, Kwok-Leung; Nemsadze, Gia; Ajimi, Maxine; Irurzun-Arana, Itziar; Lindemann, Justin; Klinowska, Teresa; Mathewson, Alastair; Morrow, Christopher; Nikolaou, Myria; Dzagnidze, Giorgi
SERENA-1: Results from a Phase 1 study (Parts I/J) testing the next-generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) in combination with capivasertib in women with ER+, HER2 advanced breast cancer

SERENA-1: 1期研究 (I/J部分) 的结果，该研究测试了ER，HER2晚期乳腺癌女性的下一代口服选择性雌激素受体降解剂 (SERD) camizestrant (AZD9833) 与capivasertib的组合

CANCER RESEARCH
IF16.6
2024-05-021
PRE
Vaklavas, Christos; Oliveira, Mafalda; Armstrong, Anne; Moreno, Irene; Twelves, Chris; Ruiz, Ivan Victoria; Bermejo, Begona; Ajimi, Maxine; Brier, Tim; Ciardullo, Carmela; Gibbons, Lisa; Irurzun-Arana, Itziar; Jack, Tony; Klinowska, Teresa; Lindemann, Justin; Mathewson, Alastair; Morrow, Christopher; Sykes, Andy; Baird, Richard
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

下一代口服选择性雌激素受体降解剂Camizestrant (AZD9833) 抑制ER乳腺癌生长并克服内分泌和CDK4/6抑制剂抗性

CANCER RESEARCH
IF16.6
2023-09-1916
OAAI
Lawson, Mandy; Cureton, Natalie; Ros, Susana; Cheraghchi-Bashi, Azadeh; Urosevic, Jelena; D'Arcy, Sophie; Delpuech, Oona; Dupont, Michelle; Fisher, David I.; Gangl, Eric T.; Lewis, Hilary; Trueman, Dawn; Wali, Neha; Williamson, Stuart C.; Moss, Jennifer; Montaudon, Elodie; Derrien, Heloise; Marangoni, Elisabetta; Miragaia, Ricardo J.; Gagrica, Sladjana; Morentin-Gutierrez, Pablo; Moss, Thomas A.; Maglennon, Gareth; Sutton, Daniel; Polanski, Radoslaw; Rosen, Alan; Cairns, Jonathan; Zhang, Pei; Sanchez-Guixe, Monica; Serra, Violeta; Critchlow, Susan E.; Scott, James S.; Lindemann, Justin P. O.; Barry, Simon T.; Klinowska, Teresa; Morrow, Christopher J.; Carnevalli, Larissa
The next generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) is active against wild type and mutant estrogen receptor α
CANCER RESEARCH
IF16.6
2023-03-012
OA
Morrow, Christopher; Carnevalli, Larissa; Baird, Richard D.; Brier, Tim; Ciardullo, Carmela; Cureton, Natalie; Lawson, Mandy; McEwen, Robert; Nikolaou, Myria; Armstrong, Anne; Bermejo, Begona; Calvo, Emiliano; Ciruelos, Eva; Garcia-Corbacho, Javier; Hamilton, Erika; Incorvati, Jason; Kabos, Peter; Oliveira, Mafalda; Patel, Manish R.; Ruiz-Borrego, Manuel; Turner, Nicholas; Twelves, Chris; Vaklavas, Christos; Carroll, Danielle; Ching, Steven; Cvetesic, Nevena; DuPont, Michelle; Gibbons, Lisa; Mathewson, Alastair; Maudsley, Rhiannon; Gutierrez, Pablo Morentin; Reddy, Avinash; Rodriguez-Canales, Jaime; Ros, Susana; Sudhan, Dhivya; Sykes, Andy; Whitson, David; Klinowska, Teresa; Lindemann, Justin
SERENA-1: Updated analyses from a Phase 1 study of the next generation oral selective estrogen receptor degrader camizestrant (AZD9833) combined with abemaciclib, in women with ER-positive, HER2-negative advanced breast cancer
CANCER RESEARCH
IF16.6
2023-03-017
OA
Turner, Nicholas; Vaklavas, Christos; Calvo, Emiliano; Garcia-Corbacho, Javier; Incorvati, Jason; Borrego, Manuel Ruiz; Twelves, Chris; Armstrong, Anne; Bermejo, Begona; Hamilton, Erika; Oliveira, Mafalda; Ciruelos, Eva; Kabos, Peter; Patel, Manish R.; Borrell, Maria; Burris, Howard; de Paula, Bruno; Falcon, Alejandro; Hernando, Cristina; Moreno, Irene; O'Brien, Ciara S.; Shagisultanova, Elena; Ruiz, Ivan Victoria; Wang, Judy S.; Wei, Mei; Brier, Tim; Carroll, Danielle; Ciardullo, Carmela; Gibbons, Lisa; Irurzun-Arana, Itziar; Jack, Tony; Kirova, Bistra; Klinowska, Teresa; Lindemann, Justin; Maidment, Julie; Mathewson, Alastair; Maudsley, Rhiannon; McEwen, Robert; Morrow, Christopher; Sykes, Andy; Baird, Richard D.
Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial
CANCER RESEARCH
IF16.6
2023-03-0136
PRE
Oliveira, Mafalda; Pominchuck, Denys; Nowecki, Zbigniew; Hamilton, Erika; Kulyaba, Yaroslav; Andabekov, Timur; Hotko, Yevhen; Melkadze, Tamar; Nemsadze, Gia; Neven, Patrick; Semegen, Yuriy; Vladmirov, Vladmir; Zamagni, Claudio; Denys, Hannelore; Forget, Frederic; Horvath, Zsolt; Nesterova, Alfiya; Bennett, Maxine; Kirova, Bistra; Klinowska, Teresa; Lindemann, Justin; Lissa, Delphine; Mathewson, Alastair; Morrow, Christopher; Traugottova, Zuzana; Van Zyl, Ruaan; Arkania, Ekaterine
Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection

ER阳性/HER2-negative晚期乳腺癌循环肿瘤细胞基因组改变的系列监测: 精确肿瘤生物标志物检测的可行性

MOLECULAR ONCOLOGY
IF4.5
2021-12-2011
OAAI
Cani, Andi K.; Dolce, Emily M.; Darga, Elizabeth P.; Hu, Kevin; Liu, Chia-Jen; Pierce, Jackie; Bradbury, Kieran; Kilgour, Elaine; Aung, Kimberly; Schiavon, Gaia; Carroll, Danielle; Carr, T. Hedley; Klinowska, Teresa; Lindemann, Justin; Marshall, Gayle; Rowlands, Vicky; Harrington, Elizabeth A.; Barrett, J. Carl; Sathiyayogan, Nitharsan; Morrow, Christopher; Sero, Valeria; Armstrong, Anne C.; Baird, Richard; Hamilton, Erika; Im, Seock-Ah; Jhaveri, Komal; Patel, Manish R.; Dive, Caroline; Tomlins, Scott A.; Udager, Aaron M.; Hayes, Daniel F.; Paoletti, Costanza
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
NPJ BREAST CANCER
IF7.6
2021-04-1624
OAAI
Smyth, Lillian M.; Batist, Gerald; Meric-Bernstam, Funda; Kabos, Peter; Spanggaard, Iben; Lluch, Ana; Jhaveri, Komal; Varga, Andrea; Wong, Andrea; Schram, Alison M.; Ambrose, Helen; Carr, T. Hedley; de Bruin, Elza C.; Salinas-Souza, Carolina; Foxley, Andrew; Hauser, Joana; Lindemann, Justin P. O.; Maudsley, Rhiannon; McEwen, Robert; Moschetta, Michele; Nikolaou, Myria; Schiavon, Gaia; Razavi, Pedram; Banerji, Udai; Baselga, Jose; Hyman, David M.; Chandarlapaty, Sarat
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers

PARP抑制剂Olaparib和AKT抑制剂Capivasertib在BRCA1/2和Non-BRCA1/2突变型癌症患者中的I期试验

CANCER DISCOVERY
IF33.3
2020-10-0192
OAAI
Yap, Timothy A.; Kristeleit, Rebecca; Michalarea, Vasiliki; Pettitt, Stephen J.; Lim, Joline S. J.; Carreira, Suzanne; Roda, Desamparados; Miller, Rowan; Riisnaes, Ruth; Miranda, Susana; Figueiredo, Ines; Rodrigues, Daniel Nava; Ward, Sarah; Matthews, Ruth; Parmar, Mona; Turner, Alison; Tunariu, Nina; Chopra, Neha; Gevensleben, Heidrun; Turner, Nicholas C.; Ruddle, Ruth; Raynaud, Florence, I; Decordova, Shaun; Swales, Karen E.; Finneran, Laura; Hall, Emma; Rugman, Paul; Lindemann, Justin P. O.; Foxley, Andrew; Lord, Christopher J.; Banerji, Udai; Plummer, Ruth; Basu, Bristi; Lopez, Juanita S.; Drew, Yvette; de Bono, Johann S.
Capivasertib (AZD5363) in combination with fulvestrant in PTEN-mutant ER plus metastatic breast cancer
CANCER RESEARCH
IF16.6
2020-02-150
PRE
Smyth, Lillian M.; Batist, Gerald; Meric-Bernstam, Funda; Kabos, Peter; Spanggaard, Iben; Lluch, Ana; Schram, Alison; Varga, Andrea; Wong, Andrea; Ambrose, Helen; Barnicle, Alan; Carr, T. Hedley; de Bruin, Elza C.; Salinas-Souza, Carolina; Foxley, Andrew; Hauser, Joana; Lindemann, Justin P. O.; Maudsley, Rhiannon; McEwen, Robert; Moschetta, Michele; Roudier, Martine; Schiavon, Gaia; Razavi, Pedram; Banerji, Udai; Chandarlapaty, Sarat; Baselga, Jose; Hyman, David M.
A pre-surgical, window of opportunity study comparing the novel oral SERD AZD9496 with fulvestrant in patients with newly diagnosed ER+HER2-primary breast cancer
CANCER RESEARCH
IF16.6
2020-02-152
PRE
Robertson, John F. R.; Evans, Abigail; Henschen, Stephan; Kirwan, Cliona; Jahan, Ali; Kenny, Laura; Dixon, J. Michael; Schmid, Peter; Kothari, Ashutosh; Mohamed, Omar; Fasching, Peter A.; Cheung, Kwok-Leung; Wuerstlein, Rachel; Carroll, Danielle; Klinowska, Teresa; Lindemann, Justin P. O.; MacDonald, Alexander; Mather, Richard; Maudsley, Rhiannon; Moschetta, Michele; Nikolaou, Myria; Roudier, Martine P.; Sarvotham, Tinnu; Schiavon, Gaia; Zhou, Diansong; Zhou, Li; Harbeck, Nadia
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population
ANNALS OF ONCOLOGY
IF65.4
2019-05-0170
OAAI
Turner, N. C.; Alarcon, E.; Armstrong, A. C.; Philco, M.; Lopez Chuken, Y. A.; Sablin, M. -P.; Tamura, K.; Gomez Villanueva, A.; Perez-Fidalgo, J. A.; Cheung, S. Y. A.; Corcoran, C.; Cullberg, M.; Davies, B. R.; de Bruin, E. C.; Foxley, A.; Lindemann, J. P. O.; Maudsley, R.; Moschetta, M.; Outhwaite, E.; Pass, M.; Rugman, P.; Schiavon, G.; Oliveira, M.
nCirculating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial
CLINICAL CANCER RESEARCH
IF10.2
2018-12-0346
OAAI
Paoletti, Costanza; Schiavon, Gaia; Dolce, Emily M.; Darga, Elizabeth P.; Carr, T. Hedley; Geradts, Joseph; Hoch, Matthias; Klinowska, Teresa; Lindemann, Justin; Marshall, Gayle; Morgan, Shethah; Patel, Parul; Rowlands, Vicky; Sathiyayogan, Nitharsan; Aung, Kimberly; Hamilton, Erika; Patel, Manish; Armstrong, Anne; Jhaveri, Komal; Im, Seock-Ah; Iqbal, Nadia; Butt, Fouziah; Dive, Caroline; Harrington, Elizabeth A.; Barrett, J. Carl; Baird, Richard; Hayes, Daniel F.
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers
CLINICAL CANCER RESEARCH
IF10.2
2018-04-30114
OAAI
Banerji, Udai; Dean, Emma J.; Alejandro Perez-Fidalgo, J.; Batist, Gerald; Bedard, Philippe L.; You, Benoit; Westin, Shannon N.; Kabos, Peter; Garrett, Michelle D.; Tall, Mathew; Ambrose, Helen; Barrett, J. Carl; Carr, T. Hedley; Cheung, S. Y. Amy; Corcoran, Claire; Cullberg, Marie; Davies, Barry R.; de Bruin, Elza C.; Elvin, Paul; Foxley, Andrew; Lawrence, Peter; Lindemann, Justin P. O.; Maudsley, Rhiannon; Pass, Martin; Rowlands, Vicky; Rugman, Paul; Schiavon, Gaia; Yates, James; Schellens, Jan H. M.

研究方向

暂未获取到该数据
T
Teresa Klinowska
H 指数:32论文数:249被引数:6,388
A
Anne Armstrong
H 指数:41论文数:357被引数:1.3万
C
Christopher J. Morrow
H 指数:27论文数:189被引数:3,772
R
Rhiannon Maudsley
H 指数:11论文数:49被引数:703
R
Richard D. Baird
H 指数:41论文数:369被引数:1.2万
M
Mafalda Oliveira
H 指数:48论文数:564被引数:1.3万
N
Nicholas C. Turner
H 指数:92论文数:1,157被引数:4.5万
A
Andrew Foxley
H 指数:16论文数:73被引数:2,523
J
J.F.R. Robertson
H 指数:73论文数:406被引数:2.2万
C
Christos Vaklavas
H 指数:27论文数:154被引数:2,931